ALLO Allogene Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLO

Price (delayed)

$1.98

Market cap

$684.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$635.15M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 74
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 38
Highlights
Allogene Therapeutics's equity has surged by 56% QoQ and by 27% YoY
The EPS has grown by 40% YoY and by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allogene.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ALLO

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
-4.35%
1 week
0.51%
1 month
2.59%
1 year
90.38%
YTD
44.53%
QTD
-4.81%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$4.64M
Gross profit
$4.64M
Operating income
-$180.32M
Net income
-$165.49M
Gross margin
100%
Net margin
-3,566.7%
The net income has increased by 30% YoY and by 4.8% QoQ
ALLO's operating income is up by 29% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does ALLO's price correlate with its fundamentals

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
1.57
P/S
140.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
136.89
The EPS has grown by 40% YoY and by 13% from the previous quarter
Allogene Therapeutics's equity has surged by 56% QoQ and by 27% YoY
ALLO's price to book (P/B) is 12% more than its last 4 quarters average of 1.4 and 4.7% more than its 5-year quarterly average of 1.5

Efficiency

How efficient is Allogene Therapeutics business performance
The return on assets has increased by 18% year-on-year and by 9% since the previous quarter
The return on equity has increased by 15% year-on-year and by 11% since the previous quarter
ALLO's return on invested capital is up by 15% year-on-year and by 11% since the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
The company's total assets rose by 39% QoQ and by 17% YoY
ALLO's quick ratio is up by 21% year-on-year and by 11% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
Allogene Therapeutics's equity has surged by 56% QoQ and by 27% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.